RP3 + carboplatin + paclitaxel + nivolumab

RP3 + carboplatin + paclitaxel + nivolumab is an investigational combination regimen comprising the oncolytic immunotherapy RP3, the platinum-based chemotherapy carboplatin, the taxane chemotherapy paclitaxel, and the immune checkpoint inhibitor nivolumab. - **RP3**: An engineered oncolytic herpes simplex virus (HSV) designed to selectively infect and lyse tumor cells and stimulate anti-tumor immune responses. - **Carboplatin**: A small molecule platinum-based chemotherapeutic that induces DNA crosslinking and cell death in rapidly dividing tumor cells. - **Paclitaxel**: A small molecule microtubule inhibitor that disrupts mitosis by stabilizing microtubules, causing cell cycle arrest and apoptosis in tumor cells. - **Nivolumab**: A fully human IgG4 monoclonal antibody targeting programmed death-1 (PD-1), an immune checkpoint receptor on activated T cells. By blocking the PD-1 pathway, it releases inhibitory signals and restores anti-tumor T cell activity[2][3][4][5]. This combination is under clinical investigation for the treatment of advanced solid tumors, aiming to synergize direct tumor cell killing with enhanced anti-tumor immunity.

Other names

carboplatinpaclitaxel